Modulatory effect of empagliflozin on cellular parameters of endocrine pancreas in experimental pre-diabetes.

Modulatory effect of empagliflozin on cellular parameters of endocrine pancreas in experimental pre-diabetes. Ann Anat. 2019 May 17;: Authors: Abdel-Hamid AAM, Firgany AEL Abstract The effect of empagliflozin (EMPA), a sodium-glucose cotransporter 2 inhibitor (SGLT2i), on the structure of endocrine pancreas in pre-diabetes (Pre-DM) is not yet elucidated. In the current study the relatively enlarged islets of Langerhans seen in the Pre-DM group was restored to control size by administration of EMPA. In addition the disbalance in the percentage of β-cells and α-cells in islets of the Pre-DM was corrected in the Pre-DM + EMPA group with reversal of the significantly increased islet mass, β-cell mass and neogenesis. Administrating EMPA in Pre-DM decreased level of caspase-3, increased that of Bcl-2 to control level and reduced the significantly increased inflammatory cytokines to levels approximated to those of the control group. In Pre-DM + EMPA group, EMPA had efficiently restored the significantly impaired glucose hemostasis to levels nearly similar to those of the control animals. This may indicate that the modulatory effect of EMPA on cells of the islets in Pre-DM is associated with a local pleotropic effect on inflammatory cytokines. PMID: 31108190 [PubMed - as supplied by publisher]
Source: Annals of Anatomy - Category: Anatomy Authors: Tags: Ann Anat Source Type: research